期刊
CLINICS IN LIVER DISEASE
卷 15, 期 3, 页码 597-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2011.05.014
关键词
Protease inhibitor; Second wave; Hepatitis C virus; Antiviral therapy
Infection with the hepatitis C virus (HCV) is a major cause of chronic liver disease and a leading indication of liver transplantations worldwide. The current standard of care for chronic hepatitis C is a combination of pegylated interferon-alpha and ribavirin that is effective in slightly more than half of cases and is associated with significant side effects. The first directly acting antivirals recently reached the US market, but will have shortcomings that should in part be overcome by the second-wave PIs that are in development. This article gives an overview of the compounds that will soon be available.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据